|Bid||0.0000 x 1200|
|Ask||0.0000 x 800|
|Day's Range||1.6000 - 1.6500|
|52 Week Range||1.5500 - 6.4400|
|Beta (5Y Monthly)||2.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 01, 2023 - Nov 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.10|
Subscribe to Yahoo Finance Plus to view Fair Value for DMTK
SAN DIEGO, September 21, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard. The award was granted pursuant to the terms of Mr. Aguillard’s employment letter and as a material inducement to his joining the Company as chief commercial officer.
SAN DIEGO, September 19, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark). The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test (DMT). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, Wes
On September 11, 2023, Kevin Sun, the Chief Financial Officer (CFO) of DermTech Inc (NASDAQ:DMTK), sold 9,616 shares of the company.